Alnylam vs. Ionis: Evaluating the Better Beaten-Down Biotech Buy
Yahoo Finance ·
Both Alnylam Pharmaceuticals and Ionis Pharmaceuticals have experienced severe stock price declines through 2026, driven by a series of unfortunate corporate challenges. In July, Alnylam lowered its revenue outlook following softer-than-anticipated sales for its core product, Amvuttra. Meanwhile, Ionis faced two major clinical setbacks on July 9, 2026, when Eplontersen missed its primary goal in a Phase 3 ATTR-CM study, and partner Roche abandoned a Huntington's disease candidate developed by Ionis. When comparing their financial standing, a clear leader emerges. Alnylam reported a remarkable 74 percent year-over-year revenue surge to 1.17 billion dollars in its most recent quarter, alongside an adjusted profit of 251.8 million dollars. In stark contrast, Ionis saw its second-quarter 2026 revenue drop by approximately 41 percent to 268 million dollars, accompanied by an adjusted quarterly loss of 57 million dollars.
AI 시장 분석
In 2026, Alnylam and Ionis experienced stock weakness but showed distinct performance differences. Alnylam lowered its revenue guidance due to weak Amvuttra sales, but recent quarterly revenue surged 74% to $1.17 billion. On the other hand, Ionis saw revenue drop 41% due to a Phase 3 trial failure and partnership termination, posting a net loss of $570,000. Investors are evaluating Alnylam, with its clear earnings rebound, as a more attractive dip-buying opportunity.
상승 영향
- Biotechnology — Alnylam proved solid financial resilience by recording a 74% year-over-year surge in recent quarterly revenue to $1.17 billion and achieving an adjusted net income of $251.8 million.
하락 영향
- Biotechnology — Ionis suffered significant fundamental damage as revenue dropped 41% and it recorded an adjusted net loss of $570,000 due to Phase 3 trial failures and partner development terminations.
DYAX 전담 분석
Alnylam proved its financial superiority by recording a 74% year-over-year surge in revenue to $1.17 billion and achieving an adjusted net income of $251.8 million. Despite concerns over guidance cuts, the strong growth of its core business acts as a factor supporting the downside of the stock price.
The bull case is margin improvement through the sales recovery of its core treatment Amvuttra, and the bear case is the slowdown of additional growth drivers due to intensifying competition. Future quarterly revenue growth rates and pipeline progress must be monitored as key indicators.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
492 participants
Related News
- Vannor Unveils Agentic Marketing Following a 30-Fold Jump in Google First-Page Rankings
- Meta Plans to Construct Massive Subsea Cable Network
- Tim Cook's Remarkable Apple Legacy: Massive Revenue Growth and Stellar Returns
- Did Softer iPhone 18 Pro Demand and Memory Costs Just Rewire Apple's AI Investment Narrative?
- Tesla Shares Rally on Strong Q3 Deliveries and Positive Wall Street Outlook
- Jamie Dimon Highlights JPMorgan's Top Risk and a Key Beneficiary Stock
